Yazar "Guldiken, B." seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Association of eNOS Glu298Asp gene polymorphism with ischemic stroke in Turkish patients(Wiley-Blackwell, 2008) Guldiken, B.; Sipahi, T.; Guldiken, S.; Ustundag, S.; Turgut, N.; Budak, M.; Ozkan, H.[Abstract Not Available]Öğe Association of renal dysfunction with stroke subtypes in acute stroke patients(Medcom Ltd, 2010) Kavalci, C.; Guldiken, B.; Ustundag, S.; Guldiken, S.Objectives: There are conflicting published data about the association of renal dysfunction with cerebrovascular diseases. Both diseases have shared risk factors such as hypertension, diabetes mellitus and smoking. In the present study, the relationship of renal dysfunction with stroke subtypes and stroke severity was investigated. Materials and methods: One hundred and sixty-two acute stroke patients without known history of renal disease and 148 control subjects were enrolled in the study. Serum urea, serum creatinine level and glomerular filtration rate (GFR) as estimated by the Modification of Diet in Renal Disease formula were used to evaluate renal dysfunction. Stroke patients were divided into two groups as haemorrhagic and ischemic stroke, the latter being further subdivided into small and large vessel disease subtypes according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. Stroke severity was assessed by the modified Rankin Scale. Results: Serum creatinine and urea levels were significantly higher and GFR was significantly lower in the stroke group than the controls (p<0.001, p<0.001, p<0.001, respectively). Serum creatinine level was found significantly higher in haemorrhagic stroke than ischaemic stroke subtypes (p<0.001). There was no difference between ischemic subtypes regarding the measured renal parameters. Stroke severity correlated with increased creatinine levels (p<0.001, beta=0.404, 95% CI=1.85-3.50). Conclusion: Acute stoke patients have impaired renal function. Renal dysfunction is particularly more prominent in haemorrhagic stroke and exists probably prior to the stroke. Whether renal dysfunction is an independent risk factor for stroke needs to be clarified by large population studies. (Hong Kong j.emerg.med. 20 10; 17:22-26)Öğe Asymmetric dimethylarginine and nitric oxide levels in migraine during interictal period(Wiley-Blackwell, 2008) Guldiken, B.; Demir, M.; Guldiken, S.; Turgut, N.; Ozkan, H.; Kabayel, L.; Tugrul, A.[Abstract Not Available]Öğe Asymmetric dimethylarginine and nitric oxide levels in migraine during the interictal period(Elsevier Sci Ltd, 2009) Guldiken, B.; Demir, M.; Guldiken, S.; Turgut, N.; Ozkan, H.; Kabayel, L.; Tugrul, A.Nitric oxide (NO), which modulates endothelial function, is thought to be pivotal in the pathophysiology of migraines. The connection between migraine and cardiovascular diseases has also drawn attention to the endothelial dysfunctions and NO pathway abnormalities seen in patients with migraine. Our goal was to assess the levels of NO and the endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), in people with migraine during the interictal period. A total of 49 patients with migraine and 22 control subjects were enrolled in the study. Their plasma NO metabolites (nitrite [NO2-] and nitrate [NO3-]) and ADMA levels were measured using the enzyme-linked immunosorbent assay method, and were then compared with their cardiovascular risk factors, anthropometric measurements, and headache frequency and severity. The plasma ADMA, NO2 and NO3 levels of the patients with migraine during the interictal period did not differ from the control group, and no relationship was found between cardiovascular risk factors and migraine attack severity and frequency. We conclude that, in patients with migraine, there is no dysfunction of baseline NO and ADMA metabolism during the interictal period. (C) 2008 Elsevier Ltd. All rights reserved.Öğe The CALCA-624 (T/C) gene polymorphism according to homocysteine levels in ischemic stroke subgroups(Springer, 2015) Alkanli, N.; Ay, A.; Alkanli, S. S.; Sipahi, T.; Guldiken, B.; Celebi, C.; Atilgan, E.[Abstract Not Available]Öğe Cardiovascular adverse effects of phenytoin(Springer Heidelberg, 2016) Guldiken, B.; Remi, J.; Noachtar, SoheylPhenytoin is an established drug in the treatment of acute repetitive seizures and status epilepticus. One of its main advantages over benzodiazepines is the less sedative effect. However, the possibility of cardiovascular adverse effects with the intravenous use of phenytoin cause a reluctance to its usage, and this has lead to a search for safer anticonvulsant drugs. In this study, we aimed to review the studies which evaluated the safety of phenytoin with respect to cardiovascular adverse effects. The original clinical trials and case reports listed in PUBMED in English language between the years of 1946-2014 were evaluated. As the key words, phenytoin, diphenylhydantoin, epilepsy, seizure, cardiac toxicity, asystole, arrhythmia, respiratory arrest, hypotension, death were used. Thirty-two clinical trials and ten case reports were identified. In the case reports, a rapid infusion rate (> 50 mg/min) of phenytoin appeared as the major cause of increased mortality. In contrast, no serious cardiovascular adverse effects leading to death were met in the clinical trials which applied the recommended infusion rate and dosages. An infusion rate of 50 mg/min was reported to be safe for young patients. For old patients and patients with a cardiovascular co-morbidity, a slower infusion rate was recommended with a careful follow-up of heart rhythm and blood pressure. No cardiovascular adverse effect was reported in oral phenytoin overdoses except one case with a very high serum phenytoin level and hypoalbuminemia. Phenytoin is an effective and well tolerated drug in the treatment of epilepsy. Intravenous phenytoin is safe when given at recommended infusion rates and doses.Öğe Diagnosis of non-epileptic paroxysmal disorders and epileptic seizures(Springer, 2017) Noachtar, S.; Guldiken, B.Non-epileptic paroxysmal disorders may clinically manifest in a similar way to epileptic seizures and have to be considered in the differential diagnosis of epilepsy. Syncope, non-epileptic psychogenic seizures, paroxysmal movement disorders, migraine, transient ischemic attacks and parasomnia constitute the major differential diagnoses. A meticulous history and a third party description are useful for the differential diagnosis. Neurological, psychiatric and cardiological examinations are required for the correct differential diagnosis. The interictal electroencephalogram (EEG), which is normal in non-epileptic patients, is frequently normal in epileptic patients at the onset of seizures, but reaches a high sensitivity after repeated recordings. In equivocal cases EEG video monitoring and in the case of suspected cardiac asystole, event recorders are useful diagnostic tools.Öğe Oxidative stress and antioxidant capacity in diabetic and non-diabetic acute ischemic stroke patients(Wiley-Blackwell, 2008) Guldiken, B.; Demir, M.; Guldiken, S.; Turgut, N.; Turgut, B.; Tugrul, A.[Abstract Not Available]Öğe Polymorphisms of the angiotensin-converting enzyme and angiotensin II receptor type 1 genes and association with stroke in Turkish subjects of the Trakya region(Wiley-Blackwell, 2008) Sipahi, T.; Guldiken, B.; Budak, M.; Guldiken, S.; Ustundag, S.; Turgut, N.; Ozkan, H.[Abstract Not Available]Öğe Relationship between total anti-oxidant capacity, homocysteine levels and cognitive tests in patients with amyotrophic lateral sclerosis(Wiley-Blackwell, 2012) Kat, S.; Turgut, N.; Guldiken, B.; Demir, M.; Erbas, H.; Turgut, B.[Abstract Not Available]Öğe Soluble CD40 ligand and prolactin levels in migraine patients during the interictal period(Wiley-Blackwell, 2010) Guldiken, S.; Guldiken, B.; Demir, M.; Kabayel, L.; Ozkan, H.; Turgut, N.; Hunkar, R.[Abstract Not Available]
